HMOX1 and prostate carcinoma: In clinical case studies, the nuclear translocation of HO-1 is associated with cancer progression and poor prognosis in prostate cancer and oral carcinoma [75,76] which contributes to the chemotherapeutic resistance in chronic myelogenous leukemia [77] and myeloma cells [78].